Cover Story

Treatment of type 2 diabetes mellitus (T2DM) with glucagon-like peptide-1 receptor agonists (GLP-1RAs) leads to better glycemic control, reduced body weight, and improvement in several cardiovascular risk factors, which has been demonstrated to be accompanied by improved micro- and macrovascular outcomes. However, many patients treated with GLP-1RAs do not reach their glycemic targets, and weight loss achieved with these agents remains well below what can be attained with bariatric surgery. Therefore, there are still opportunities to improve the existing GLP-1RA class.

Coskun et al. describe a novel, single-peptide, dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, LY3298176. The dual functionality of the peptide is described in preclinical in vitro and in vivo models, and clinical assessment demonstrated that administration of LY3298176 led to decreased glucose levels and decreased body weight in healthy individuals during a multiple ascending dose study, and in a randomized, 4-week, Phase 1b trial in T2DM patients.

Full Text
The 60 Second Metabolist
In this section authors briefly report on their work recently published in Molecular Metabolism.

Watch the most recent interview by clicking the video still. The link "referring article" directs you to this author's publication.



Abdelfattah El Ouaamari
Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, USA
Referring article

Other Scientists...
Issue Alert
If you want to be alerted via email when new content that matches your interests is available, please login or register at www.sciencedirect.com/journal/molecular-metabolism
Conferences & Events
January
13 − 17
2019
Mitochondrial Biology in Heart and Skeletal Muscle
Keystone, USA
February
10 − 14
2019
Obesity and Adipose Tissue Biology
Banff, Canada
February
10 − 14
2019
Functional Neurocircuitry of Feeding and Feeding Disorders
Banff, Canada
February
24 − 28
2019
Tumor Metabolism
Keystone, USA
March
3 − 7
2019
Diabetes: Innovations, Out­comes, Personalized Therapies
Whistler, Canada
March
10 − 14
2019
Microbiome: Mechanisms and Consequences
Montreal, Canada
March
15 − 19
2019
Cancer Metastasis
Florence, Italy
Media Coverage
Supported by